Clinical Trial Update: Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients [Phase 3]

View source ↗

Summary

A Phase 3 open-label trial comparing BI 207127 to telaprevir for chronic hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BI 207127 (BI-207127)
• Telaprevir (telaprevir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatitis C, Chronic | Phase 3 | Status: WITHDRAWN